Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

in MAP0004 is dihydroergotamine (DHE), which has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE administered by injection to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 hours. MAP Pharmaceuticals is seeking to expand the use of this compound to treat migraines early, non-invasively and with a fast onset of action.

MAP Pharmaceuticals is initiating the first Phase 3 trial of its MAP0004 product candidate pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. The SPA is intended to provide assurance that if pre-specified trial results are achieved, they may serve as the primary basis for an efficacy claim in support of a new drug application. In general, these assessments are considered binding on the FDA as well as the sponsor unless public health concerns unrecognized at the time the SPA is entered into become evident or other new scientific concerns regarding product safety or efficacy arise.

About Migraine

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States. It presents with recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. Most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.

In published studies, migraine sufferers often cite faster onset of pain relief and lower incidence of migraine recurrence as two key therapeutic attributes they would like from their medication. Currently approved drugs for the treatment of an acute migraine attack do not fully meet the needs of all patients due to the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increa
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 23, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... infringement lawsuit against Santaris Pharma A/S and Santaris Pharma ... the Southern District of California.  Isis, infringement suit against ... and antisense drug discovery services to several pharmaceutical companies. ...
... Sept. 23, 2011 Amgen (NASDAQ: AMGN ... Vectibix® (panitumumab) studies will be presented at the 2011 ... in Stockholm, Sweden.   "The data being ... Amgen,s ongoing commitment to advancing the understanding of cancer ...
Cached Medicine Technology:Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 2Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 2Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 4Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 5Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 6Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 7Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 8Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 9Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 10
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... are more likely to start smoking or drinking with ... (ADHD) or conduct disorder, new research suggests. ... the risk of substance use as [these] children approach ... at Cincinnati Pediatric Research Group, which is part of ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... ... orthodontist, Dr. Inna Gellerman, kicks off holiday season with food drives, toy drives and ... ... , Dr. Inna Gellerman, celebrates the holiday season by participating in various community events, ...
... ... Medtronic founder, joins Dr. Jean Watson to launch The Million Nurse Global ... www.millionnurseproject.org ! . Nurses are uniting to celebrate the 2010 ... and two proposed United Nations Resolutions, together to radiate heart-centered Love and ...
... , ... With over 45 million uninsured in the ... Obama’s plans for health insurance reform in the United States, one ... transcends traditional boundaries. MediBid connects physicians to patients in a free-market ...
... ... has announced that they have added a new line of Natural ... Vitamins are produced on FDA registered and inspected facility operating since ... Medicine’s Nutritional vitamins and supplements make them safe, top quality products. ...
... ... company and "Top 100" Rochester, NY Growth Company, is partnering with AstraZeneca ... for the improved management of hypertension. The partnership program positions community ... a select group of Canadian retail pharmacy participants. , ...
... , AUBURN HILLS, Mich., Dec. ... integrated logistics services and highly customized supply chain solutions ... Worldwide Holdings, Inc. The terms of the transaction are ... , Addison, IL-based NAL is a third-party logistics (3PL) ...
Cached Medicine News:Health News:Long Island Children's Orthodontist, Dr. Inna Gellerman, Celebrates Season of Giving with Holiday Drives and Events 2Health News:The Million Nurse Global Caring Field Project Launches Jan. 1st, 2010 at Noon 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 2Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 4Health News:PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: